30
Participants
Start Date
November 30, 2003
Primary Completion Date
May 31, 2009
Study Completion Date
April 30, 2017
Cohort 1 anti-OX40
0.1 mg/kg anti-OX40 on days 1, 3, and 5
Cohort 2 anti-OX40
.4 mg/kg anti-OX40 on days 1, 3, and 5
Cohort 3 anti-OX40
2.0 mg/kg anti-OX40 on days 1, 3, and 5
Tetanus Day 29
Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
Tetanus Day 1
Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
KLH Day 1
1 mg KLH in 1 cc diluent subcutaneously on Day 1.
KLH Day 29
1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
Providence Cancer Center, Portland
Providence Health & Services
OTHER